Say Hello!
Don’t be shy.




Home > Companies > Oncimmune

Oncimmune profiles the body’s immune response to detect evidence of the body’s natural response to cancer, which can be detected far earlier than cancerous cells themselves, or the cancer’s DNA.

Our proprietary platform — underpinned by rapid biomarker discovery and our comprehensive immunogenic protein library of over 8,000 antigenic proteins — has a role in supporting case-selection, complementing diagnostic evidence, and facilitating therapeutic decision-making; and is a keystone to the future of cancer care.

Our patented technology measures blood levels of autoantibodies to tumour-associated antigens, the combination of which is highly specific for target cancers, whose characteristic signal can be detected four years or more before standard clinical diagnosis.